Medicare Enrolled
Dr. Gurjyot Doshi, M.D.
Hematology & Oncology · Katy, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Doshi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Doshi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Doshi
Dr. Gurjyot Doshi is a hematology & oncology specialist in Katy, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Doshi performed 51,781 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Doshi received a total of $39,259 from 52 pharmaceutical and/or device companies across 225 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Doshi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 19% volume in TX
$39,259 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗51,781
Medicare services
Top 19% in TX for hematology & oncology
Not available
Unique patients (not deduplicated)
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 12,500 | $43 | $137 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
11,220 | $0 | $5 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
8,700 | $0 | $5 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
7,870 | $2 | $20 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
6,600 | $0 | $2 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,006 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 860 | $1 | $114 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
504 | $8 | $36 |
| Injection, granisetron hydrochloride, 100 mcg | 390 | $0 | $24 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
347 | $8 | $20 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
316 | $65 | $250 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
231 | $22 | $157 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
229 | $99 | $707 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
121 | $97 | $368 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
102 | $59 | $211 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
93 | $11 | $96 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
79 | $48 | $313 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
74 | $7 | $431 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
67 | $2 | $19 |
| New patient office visit, complex (60-74 min) | 62 | $171 | $709 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 62 | $127 | $3,675 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
59 | $12 | $108 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
53 | $23 | $161 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
49 | $52 | $344 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
41 | $1 | $7 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
40 | $26 | $145 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
37 | $45 | $289 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
24 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
24 | $6 | $34 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
21 | $20 | $114 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
22.9% high complexity
74.2% medium
2.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$39,259
Total received (2018-2024)
Avg $5,608/year across 7 years
Top 14% in TX for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
52
Companies
225
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,826
2023
$1,482
2022
$2,040
2021
$3,696
2020
$13,890
2019
$8,709
2018
$7,616
Payments by company (2024)
PFIZER INC.
$232
Novartis Pharmaceuticals Corporation
$177
GENZYME CORPORATION
$129
Merck Sharp & Dohme LLC
$115
SEAGEN INC.
$100
Karyopharm Therapeutics Inc.
$95
Incyte Corporation
$82
Astellas Pharma US Inc
$77
Janssen Biotech, Inc.
$76
ABBVIE INC.
$76
PUMA BIOTECHNOLOGY, INC.
$61
Eisai Inc.
$55
Daiichi Sankyo Inc.
$51
Gilead Sciences, Inc.
$47
Adaptive Biotechnologies Corporation
$35
BeiGene USA, Inc.
$33
Celgene Corporation
$33
TerSera Therapeutics LLC
$31
Alexion Pharmaceuticals, Inc.
$31
Bayer Healthcare Pharmaceuticals Inc.
$29
Rigel Pharmaceuticals, Inc.
$28
Tempus AI, Inc
$27
JAZZ PHARMACEUTICALS INC.
$26
Deciphera Pharmaceuticals Inc.
$25
GlaxoSmithKline, LLC.
$22
Aveo Pharmaceuticals, Inc.
$22
SpringWorks Therapeutics, Inc.
$21
SERVIER PHARMACEUTICALS LLC
$19
TAIHO ONCOLOGY, INC.
$19
ADC Therapeutics America, Inc.
$18
AstraZeneca Pharmaceuticals LP
$18
Lilly USA, LLC
$17
Top 3 companies account for 29.4% of 2024 payments
All-time payments by company (2018-2024) ›
Astellas Pharma US Inc
$12,572
Janssen Biotech, Inc.
$7,407
PFIZER INC.
$7,169
Seagen Inc.
$2,889
Eisai Inc.
$2,840
Bayer HealthCare Pharmaceuticals Inc.
$2,411
Lilly USA, LLC
$361
Novartis Pharmaceuticals Corporation
$351
GlaxoSmithKline, LLC.
$218
Dendreon Pharmaceuticals LLC
$206
GENZYME CORPORATION
$200
Merck Sharp & Dohme LLC
$194
Celgene Corporation
$168
Karyopharm Therapeutics Inc.
$140
Incyte Corporation
$132
AstraZeneca Pharmaceuticals LP
$132
Apellis Pharmaceuticals, Inc.
$120
BeiGene USA, Inc.
$112
EMD Serono, Inc.
$102
Amgen Inc.
$100
SEAGEN INC.
$100
Gilead Sciences, Inc.
$97
Seattle Genetics, Inc.
$92
Pharmacyclics LLC, An AbbVie Company
$92
Adaptive Biotechnologies Corporation
$92
ABBVIE INC.
$76
Alexion Pharmaceuticals, Inc.
$65
Deciphera Pharmaceuticals Inc.
$64
Foundation Medicine, Inc.
$63
PUMA BIOTECHNOLOGY, INC.
$61
E.R. Squibb & Sons, L.L.C.
$58
EISAI INC.
$55
TerSera Therapeutics LLC
$52
Daiichi Sankyo Inc.
$51
Exelixis Inc.
$38
Janssen Pharmaceuticals, Inc
$32
SOBI, INC
$31
Bayer Healthcare Pharmaceuticals Inc.
$29
Rigel Pharmaceuticals, Inc.
$28
Tempus AI, Inc
$27
JAZZ PHARMACEUTICALS INC.
$26
AbbVie Inc.
$24
Aveo Pharmaceuticals, Inc.
$22
SpringWorks Therapeutics, Inc.
$21
SERVIER PHARMACEUTICALS LLC
$19
TAIHO ONCOLOGY, INC.
$19
ADC Therapeutics America, Inc.
$18
Regeneron Healthcare Solutions, Inc.
$18
Genentech USA, Inc.
$17
OnMark, Inc.
$16
Clovis Oncology, Inc.
$15
Boehringer Ingelheim Pharmaceuticals, Inc.
$14
Top 3 companies account for 69.2% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · BAVENCIO · BLENREP · BOSULIF · BRUKINSA · Balversa · Blincyto · CALQUENCE · CARVYKTI · CYRAMZA · Cabometyx · Columvi · DARZALEX · Dayvigo · Doptelet · ELIQUIS · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Empaveli · Enhertu · Erleada · FOTIVDA · FOUNDATIONONE · Fabhalta · GILOTRIF · IBRANCE · IMBRUVICA · INLYTA · JAKAFI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUPRON DEPOT · Lenvima · MONJUVI · OGSIVEO · OJJAARA · OPDIVO · PADCEV · PROMACTA · PROVENGE · Padcev · Pomalyst · QINLOCK · Revlimid · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · Stivarga · TABRECTA · TAGRISSO · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · Vanflyta · Voranigo · XARELTO · XPOVIO · XT CDX · XTANDI · Xofigo · Xospata · Xtandi · ZEJULA · ZEPZELCA · Zoladex · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
27
County median income
$73,104
Nearest hospital to ZIP centroid (approximate)
MEMORIAL HERMANN KATY HOSPITAL
7.6 mi
7.6 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Doshi is a mixed practice specialist, with above-average Medicare volume (top 19% in TX), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Doshi experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Doshi performed 12,500 pembrolizumab injection (keytruda) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Doshi receive payments from pharmaceutical companies?
Yes. Dr. Doshi received a total of $39,259 from 52 companies across 225 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Doshi's costs compare to other hematology & oncology specialists in Katy?
Dr. Doshi's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Doshi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Katy
Browse hematology & oncology specialists in Katy ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology